Background: A novel subcutaneous allergen immunotherapy formulation (gpASIT+
| INTRODUCTION
Advances in allergen immunotherapy (AIT), particularly in subcutaneous (SCIT) and sublingual immunotherapy (SLIT), aim to further reduce safety concerns for severe systemic reactions (SRs) and anaphylaxis as well as to increase real-life effectiveness, particularly by improving compliance and acceptance among patients through shorter treatment with a more convenient product. 1 To achieve these goals, novel therapeutics have been developed to overcome the limitations of natural allergens' intrinsic features. Recent investigations on peptide immunotherapy focus on synthetic peptide immunoregulatory epitopes (SPIREs) containing T cell-reactive short peptides 2 and longer continuous overlapping peptides (COPs) 3 of up to 80 amino acids. 4 Sets of long COPs that encompass all potential T-cell epitopes without IgE conformations induce IgG 4 but also evoke late asthmatic responses at high concentrations. 4, 5 Mixtures containing grass allergens from the Pooideae subfamily have been shown to possess no advantage over single grass allergen extracts, which produced completely cross-reactive IgG 4 and were substituted for multiple grass subfamilies. 6, 7 Perennial ryegrass (Lolium perenne, L. perenne) contains group 1, 2/3, 4, 5, 11, 12 and 13 allergens. 6 Lolium perenne, like the other members of the Pooideae subfamily, possesses strong cross-allergenicity, which is attributable to the high homology of groups 1, 2/3 and 5. 8 In this trial, different lengths of L. perenne peptides (LPPs) obtained from enzymatic hydrolysis were administered subcutaneously in a short up-dosing phase. We determined the optimum dose of LPP in terms of safety as well as clinical and immunological effects in patients with seasonal allergic rhinoconjunctivitis (SAR).
2 | ME TH ODS
| Trial design
This randomized, parallel-group, double-blind, placebo-controlled, dose-finding trial was conducted at 23 outpatient study centres.
Patients were screened in mid-August 2014, and enrolled partici- Table S1 in this article's Online Repository.
| Study medication
The adjuvant-free immunotherapy peptides used in this trial were extracted from whole ryegrass pollen by enzymatic digestion and formulated for subcutaneous injections according to good manufacturing practice requirements (see Online Repository Methods) as described by Shamji et al. 9 ASIT biotech s.a. (Brussels, Belgium) provided labelled LPP and placebo treatment kits (per visit and treatment number). 
| Planned interventions and timing

| Conjunctival provocation test
Conjunctival provocation tests (CPTs) were conducted 11 and recorded 12 as described before. The allergen extract ALK-lyophilized grass (ALK-Abell o, Wedel, Germany) was used in concentrations of 100, 1000 and 10 000 SQ-U/mL. CPT responses ≥ stage II according to the Riechelmann scale 11 were considered positive. If baseline CPT responses at V1 and V2 differed by one concentration stage, the higher concentration step was used for further analyses. CPTs were performed at baseline, V6 and V7. At V2 and V6, CPTs were conducted before the study medication was administered.
The CPT score was calculated as follows: 0 = no reaction at all, 1 = reaction at 10 000 SQ-U/mL, 2 = reaction at 1000 SQ-U/mL and 3 = reaction at 100 SQ-U/mL. To calculate the mean composite score, CPT scores of all grass allergen concentrations used in the individual tests were combined as described before. 13, 14 Conjunctival provocation test (CPT) results are a predictive surrogate marker for SAR severity, as reduced CPT reactivity after The primary efficacy endpoint was defined as the proportion of patients whose CPT reactivity to the different allergen extract concentrations decreased from baseline to V7. The secondary efficacy endpoints included the proportion of patients whose CPT reactivity to the different allergen extract concentrations decreased from baseline to V6, composite and CPT score reductions, as well as immunological changes.
| Immunological responses
Sera were collected from all patients at the screening visit (V1) and at the follow-up visit (V7, after finishing treatment). Immunoglobulin analyses measured grass pollen-specific IgG (sIgG), IgG 4 (sIgG 4 ) and IgE (sIgE) levels using the ImmunoCap â system (Pharmacia AB, Uppsala, Sweden).
The production of blocking antibodies was assessed using a functional assay. [15] [16] [17] Relative allergen-IgE complex binding to CD23 detected in the presence of patient and indicator serum was expressed as the percentage of binding observed in a reference condition with indicator serum only. The production of blocking antibodies was reflected by a decrease in complex binding.
| Statistics
The sample size was calculated under the assumption that a maximum of 40% of placebo group patients and 75% or more of the actively treated patients would improve. 18 Given a 5% error and a power of 90%, Wilson's method estimated a group size of 46.
Statistical analyses were performed using SPSS version 22 (IBM Corp., Armonk, NY, USA), and data were described in means and standard errors of the mean. P values vs placebo were obtained using the two-tailed Fisher's exact test or the two-tailed MannWhitney U test, with P < .05 considered as significant.
A group sequential analysis was conducted under the null hypothesis that there would be no difference between the treatment groups regarding the proportion of patients with a reduction in CPT reactivity to a certain concentration of grass pollen allergen between baseline and V7.
3 | RESULTS
| Demographic data and baseline values
Of 240 screened patients, 198 were randomized to the placebo, 70-, Patients in the safety set showed a mean age of 36.9 years (Table 2 ). Mean duration of SAR and wheal size in the SPT for grass pollen were similar across all groups (Table 2) . Specific IgE to grass pollen was significantly higher at baseline in the 70-lg (P = .004) and 370-lg groups (P = .031) than in the placebo group. Most patients had sIgE levels belonging to classes 3 and 4
T A B L E 1 Cluster titration schedule (38.4% and 27.8%, respectively). One-fifth of the patients had asthma ( Table 2 ).
| Reduction in CPT reactivity from baseline to V7
In the mPP set, exploratory analyses showed the most prominent decrease in CPT reactivity from baseline in the group receiving 170 lg, followed by those receiving 370 lg, 70 lg and placebo ( Figure 2A ). Similarly, in the mITT set CPT reactivity decreased from baseline to V7, the greatest decrease being observed in patients receiving 170 lg, followed by those receiving 370 lg, 70 lg and placebo ( Figure S1A ).
Improvements were significantly greater in patients receiving 170 lg (P = .023 for the mPP set and P = .022 for the mITT set) than in those receiving placebo.
3.3 | Reduction in CPT reactivity from baseline to
V6
At V6, which took place 1 week after the 170-and 370-lg groups reached a cumulative dose of 170 lg, the combined group analysis of CPT reactivity showed a significant decrease (mPP set: P = .004; mITT set: P = .008) in comparison with placebo ( Figures 2B and S1B ).
| Patients no longer reacting to conjunctival provocation
In the mPP set, the percentages of patients who no longer reacted to conjunctival provocation were 39.0% (370-and 170-lg groups), 27.9%
(70-lg group) and 18.0% (placebo) after treatment completion (Figure 3 ). In the mITT set, the proportion of patients no longer reacting to conjunctival provocation at V7 was highest in the group receiving 170 lg and lowest in the placebo group ( Figure S2 ).
| Mean composite scores
At baseline, mean composite scores 13, 14 
| Immunological changes
An increase in sIgE levels was observed from baseline to V7 in the groups receiving LPP. At V7, these levels were significantly higher in the LPP groups than the sIgE level in the placebo group (P < .021) ( Figure 4A , Table S2 ).
Grass pollen-specific IgG levels also increased in the LPP groups from V1 to V7. At V7, sIgG levels were significantly higher in the LPP groups than the level in the placebo group (P < .009). Specific
IgG levels in the placebo group remained unchanged ( Figure 4B , Table S2 ).
Grass pollen-specific IgG 4 levels increased from V1 to V7 in the LPP groups but remained unchanged in the placebo group. At V7, these levels were significantly higher in the LPP groups than the sIgG 4 level in the placebo group (P < .001) ( Figure 4C , Table S2 ). Use of antihistamines was rare.
Unsolicited treatment-emergent adverse events (TEAEs, n = 156) were reported by 75 patients (36.9%) (Table S3) 
| DISCUSSION
The aim of this study in patients with allergic rhinitis was to establish an optimal dose in terms of clinical effect, clinical tolerability and safety of increasing doses of LPP when administered by subcutaneous injections. The clinical effect was assessed using the CPT, In comparison with other studies, a limited placebo effect was observed. In the mPP set at V7, 25.6% of placebo group patients showed less CPT responsiveness and 18.0% showed no reaction.
However, another trial reported that 30.0% of patients receiving placebo showed an increase in their CPT threshold concentrations. (Table S2) .
A study comparing SCIT and SLIT in terms of immunogenicity deduced that the maximum changes in sIg and blocking antibodies were reached after 3 months of treatment. Facilitated allergen binding (FAB) inhibition after 1 month was less than 5% for SCIT and nonexistent for SLIT. 30 Nevertheless, in our study, LPP immunotherapy led to FAB inhibition that after 4 weeks was 26.4% greater than that at baseline (370-lg group). Shamji et al 16 observed FAB inhibitions of 24.70% AE 1.79% after double the treatment time (8 weeks) with 100 000 SQ grass pollen SCIT (n = 108).
Cumulative doses higher than 170 lg had no additional clinical benefits but increased immunological surrogate markers in this study. This trial showed a lower percentage rate for SRs than all the above trials, with 10.1% of the patients experiencing such events.
Although that figure corresponds to 1.36% of all injections, it is important to note that this trial followed a rapid up-titration protocol, which is more likely to elicit SRs than dose maintenance phases having longer up-dosing schedules. Most TEAEs occurred at doses below 100 lg and no late SRs were observed.
As for the tolerability in terms of local reactions, all patients in our study reported mild local erythema and wheals at the injection site within the first 30 minutes at least once ( Figure S6 ). Good clinical tolerability of grass pollen carrier-based fusion proteins was shown in 60 patients with almost no immediate wheal reactions and no positive late-phase skin reactions after 48 hours of atopy patch testing. 
